68-Year-Old Woman With a History of Aggressive NHL Presents With Tongue Hyperpigmentation

Poll

A 68-year-old woman with a history of aggressive NHL developed hyperpigmented patches on her tongue two months after starting her R-CHOP chemotherapy regimen. Which medication was likely the cause, and which other location would you expect hyperpigmentation on this patient?

A 68-year-old woman with a history of aggressive stage III non-Hodgkin lymphoma (NHL) developed hyperpigmented patches on her tongue two months after starting her R-CHOP chemotherapy regimen. Which medication was likely the cause, and which other location would you expect hyperpigmentation on this patient?

What is your diagnosis?

A. Cyclophosphamide, and pigmentation of the nails
B. Vincristine, and hyperpigmentation at the popliteal fossa
C. Prednisone, and pigmentation of the wrists
D. Rituximab, and dark pigmentation of the ocular conjunctiva
Recent Videos
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
Related Content
Oncology care requires psychosocial support, nutrition, and survivorship, which can result in improved patient outcomes and quality of life.

Why Survivorship Matters: Creating Space in Multidisciplinary Cancer Care

ONCOLOGY Staff
December 5th 2025
Article

Oncology care requires psychosocial support, nutrition, and survivorship, which can result in improved patient outcomes and quality of life.

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

How to Manage Oligometastatic Kidney Cancer? Insights From IKCS 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
December 4th 2025
Podcast

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

Updated results at ASH 2025 may support new alternatives to continuous therapy and standard intensive chemotherapy across different leukemia types.

ASH 2025: Key Anticipated Updates in the Leukemia Landscape

Russ Conroy
December 4th 2025
Article

Updated results at ASH 2025 may support new alternatives to continuous therapy and standard intensive chemotherapy across different leukemia types.

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Evolutions Across NSCLC, Multiple Myeloma, and AML at Georgia Cancer Center

Girindra Raval, MD;Amany Keruakous, MD;Daniel Peters, MD
December 1st 2025
Podcast

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Developers have outlined plans to initiate a randomized phase 2 trial evaluating silevertinib in patients with newly diagnosed glioblastoma.

Silevertinib Displays Robust Antitumor Activity in EGFR-Mutated NSCLC

Roman Fabbricatore
December 4th 2025
Article

Developers have outlined plans to initiate a randomized phase 2 trial evaluating silevertinib in patients with newly diagnosed glioblastoma.

Differences in Clinical Trial Availability vs Distribution of Disease Among Gynecological Cancers

Differences in Clinical Trial Availability vs Distribution of Disease Among Gynecological Cancers

Andrea I. Nañez, MD;Maria A. Velez, MD;Mae Zakhour, MD;Edward B. Garon, MD, MS
December 4th 2025
Article